Kirk Adams, the longtime healthcare chief for the Service Employees International Union, is leaving that role to join the Healthcare Education Project, a joint effort of 1199SEIU United Healthcare Workers East and the Greater New York Hospital Association.
Supporters hope a new Medicare Advantage experiment offering lower out-of-pocket costs for high-value services and providers will become a template for health plans with sizable cost-sharing, which have become the standard offering from employers and insurers.
Leading medical-device maker Medtronic on Thursday reported a 12% jump in revenue for the first quarter of its fiscal 2016 over the same period last year, driven by its purchase of surgical-device maker Covidien in January.
The first biosimilar medication approved in the U.S. made its way to the market on Thursday, ushering in a new era of competition between such drugs and the original high-cost biologic therapies they emulate.
Highmark Health reported an operating loss of $171 million during the first six months of the year as losses soared for health plans sold in Affordable Care Act exchanges.
David Bernd, CEO of Norfolk, Va.-based Sentara Healthcare, is retiring next year. Howard Kern, Sentara's president and COO, assumes the role after Bernd's retirement, effective March 3, 2016.
HHS proposed on Thursday to ban discrimination against transgender people throughout the healthcare system, carrying out anti-bias provisions in the Affordable Care Act.
HHS and 15 other agencies issued proposed updates to what's known as the Common Rule, created to protect human research subjects. The changes, coming ahead of a major White House precision-medicine initiative, include clearer consent rules for the reuse of stored blood or tissue.
A Federal Reserve interest rate hike could come as soon as this month, but that isn't likely to deter healthcare borrowing. It may even encourage providers to accelerate spending plans to stay ahead of rising rates.
Drugmaker Pfizer says it has completed its roughly $15 billion purchase of the injectable-drug maker and infusion-device manufacturer Hospira, expanding its product offerings in a growing medical market.
The launch of Amgen's new cholesterol-lowering drug Repatha is renewing the debate over the cost of the drugs and the reasons why prices are so much higher in the U.S. than in other advanced countries.
Two papers published online Wednesday in the New England Journal of Medicine show promising results in the treatment of two rare blood disorders using an experimental therapy developed by Menlo Park, Calif., biopharmaceutical firm Geron Corp.